Efecto antifibrótico del interefrón alfa 2b recombinante en la cirrosis hepática por virus B o C

the antifibrotic effect of recombinant interferon alfa 2b used for a year (6 millions of u 3 times a week) in patients with liver cirrhosis caused by virus b or c was evaluated by histological studies and doppler echography before and after concluding the treatment. the hepatic biochemical profile was assessed during that year. 10 patients participated in the research. in the global analysis of the morphometric method applied to the histological study and in the doppler echography, it was found that there was no statistically significant reduction of liver fibrosis, but it individually decreased in 3of the patients treated and it stopped in one. the semiquantitative method for evaluating fibrosis in the liver biopsy did not show a reversion of the fibrotic process. a statistically marked improvement was observed in the aminotransferases. adverse effects coinciding with what is reported in the national and international literature reviewed were detected.